MAGE-A4 IHC 1F9 pharmDx
Agilent Technologies, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
The FDA recorded a decision dated 2026-09-11 on supplement P230016/S005 for MAGE-A4 IHC 1F9 pharmDx, an immunohistochemistry antibody assay in the Pathology specialty under product code SBL, submitted by Agilent Technologies, Inc. The supplement is a 30-Day Notice with the recorded reason Process Change - Manufacturer/Sterilizer/Packager/Supplier.
The recorded statement covers approval of manufacturing process and equipment changes for filling and capping. This is a supplement action tied to the existing P230016 file, not a new approval of the assay as a whole. The source lists no supporting documents, so the specific filling and capping equipment, sites and validation data behind the change are not identified here, and the decision code OK30 is not expanded in the available record.
Whether the changed filling and capping steps affect assay performance or labeling cannot be determined from this record; that question would require the underlying FDA review documents, which are not included.
FDA approval order statement
approval of manufacturing process and equipment changes for filling and capping
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230016/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230016 · Original PMA
MAGE-A4 IHC 1F9 pharmDx
P230016/S005 received
Application receipt date recorded by FDA.
P230016/S005 · FDA decision
30-Day Notice
P230016/S003 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S004 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGE-A4 IHC 1F9 pharmDxP230016 | Agilent Technologies, Inc. | PMA approval | Aug 1, 2024 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S003 | Agilent Technologies, Inc. | PMA supplement | Sep 15, 2026 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S004 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6392 Via Real, Carpinteria, CA, 93013
Sources and methodology
- Original FDA record: P230016/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

